IDEAYA Biosciences IDYA
$ 30.0
0.0%
Quarterly report 2024-Q3
added 11-04-2024
IDEAYA Biosciences Balance Sheet 2011-2024 | IDYA
Annual Balance Sheet IDEAYA Biosciences
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-154 M | -65.2 M | -86.9 M | - | -27.3 M | -20.5 M | -5.96 M | - | - | - | - | - | - |
Long Term Debt |
1.12 M | 1.61 M | 3.48 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
1.75 M | 1.87 M | 1.7 M | 1.54 M | 1.14 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 5.66 M | 140 M | 30.8 M | - | - | - | - | - | - |
Total Current Liabilities |
27.1 M | 31.7 M | 45.2 M | 38.6 M | 6.94 M | - | - | - | - | - | - | - | - |
Total Liabilities |
28.2 M | 38.5 M | 79.8 M | 100 M | 12.6 M | 145 M | 33.2 M | - | - | - | - | - | - |
Deferred Revenue |
- | 8.57 M | 29 M | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-348 M | -235 M | -177 M | - | -92.5 M | -50.5 M | -16.2 M | - | - | - | - | - | - |
Total Assets |
649 M | 388 M | 381 M | 298 M | 113 M | 96.5 M | 17.5 M | - | - | - | - | - | - |
Cash and Cash Equivalents |
157 M | 68.6 M | 92 M | 72 M | 34.1 M | 20.5 M | 6.03 M | - | - | - | - | - | - |
Book Value |
621 M | 349 M | 302 M | 198 M | 100 M | -48.9 M | -15.7 M | - | - | - | - | - | - |
Total Shareholders Equity |
621 M | 349 M | 302 M | 198 M | 100 M | -48.9 M | -15.7 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet IDEAYA Biosciences
2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
18.8 M | 1.26 M | 1.26 M | 1.12 M | - | 611 K | 1.12 M | 1.61 M | 2.1 M | 2.57 M | 3.03 M | 3.48 M | 3.92 M | 4.36 M | 4.77 M | 5.18 M | 5.18 M | 5.18 M | 5.18 M | 5.63 M | 5.63 M | 5.63 M | 5.63 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
59.5 M | 42 M | 26.2 M | 28.2 M | 24.9 M | 25.9 M | 30.9 M | 38.5 M | 42.1 M | 68.7 M | 70.2 M | 79.8 M | 81.8 M | 88.1 M | 93 M | 100 M | 100 M | 100 M | 100 M | 12.6 M | 12.6 M | 12.6 M | 12.6 M | 7.1 M | 7.1 M | 7.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | 1.44 M | 2.82 M | 6.26 M | 8.57 M | 10.3 M | 35.8 M | 39.2 M | 29 M | 22.9 M | 22.1 M | 25.5 M | 27.6 M | 27.6 M | 27.6 M | 27.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-493 M | -441 M | -388 M | -348 M | -314 M | -287 M | -259 M | -235 M | -211 M | -213 M | -191 M | -177 M | -159 M | -147 M | -136 M | -127 M | -127 M | -127 M | -127 M | -92.5 M | -92.5 M | -92.5 M | -92.5 M | -50.5 M | -50.5 M | -50.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
1.24 B | 974 M | 962 M | 649 M | 533 M | 528 M | 365 M | 388 M | 411 M | 338 M | 359 M | 381 M | 399 M | 328 M | 326 M | 298 M | 298 M | 298 M | 298 M | 113 M | 113 M | 113 M | 113 M | 96.5 M | 96.5 M | 96.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
400 M | 183 M | 108 M | 157 M | 152 M | 103 M | 67.2 M | 68.6 M | 102 M | 49.1 M | 55.3 M | 92 M | 108 M | 90.4 M | 137 M | 72 M | 72 M | 72 M | 72 M | 34.1 M | 34.1 M | 34.1 M | 34.1 M | 20.5 M | 20.5 M | 20.5 M | - | 5.96 M | - | - | - | 9.69 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
1.18 B | 932 M | 935 M | 621 M | 508 M | 502 M | 334 M | 349 M | 369 M | 269 M | 289 M | 302 M | 318 M | 240 M | 233 M | 198 M | 198 M | 198 M | 198 M | 100 M | 100 M | 100 M | 100 M | 89.4 M | 89.4 M | 89.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
1.18 B | 932 M | 935 M | 621 M | 508 M | 502 M | 334 M | 349 M | 369 M | 269 M | 289 M | 302 M | 318 M | 240 M | 233 M | 198 M | 198 M | 198 M | 198 M | 100 M | 100 M | 100 M | 100 M | -48.9 M | -48.9 M | -48.9 M | -21.3 M | -15.7 M | - | - | - | -4.13 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency